MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man

Circulation

Volumn 88, Issue 4, 1993, Pages 1512-1517

  Peerlinck, K ^a   De Lepeleire, I ^b   Goldberg, M ^c   Farrell, D ^c   Barrett, J ^c   Hand, E ^c   Panebianco, D ^c   Deckmyn, H ^a   Vermylen, J ^a   Arnout, J ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b MERCK RESEARCH LABORATORIES   (United States)

^c O and N ^*

Author keywords

Antihrombotic drug; Antiplatelet agents; Bleeding time; Fibrinogen receptor; Integrin

Indexed keywords

ANTICOAGULANT AGENT; N (BUTYLSULFONYL) O [4 (4 PIPERIDYL)BUTYL]TYROSINE; TIROFIBAN; TYROSINE DERIVATIVE; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 2;

ANTICOAGULANT THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DRUG ACTIVITY; DRUG MECHANISM; DRUG TOLERANCE; DRUG USE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOGENESIS;

BLEEDING TIME; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMAN; IN VITRO; INFUSIONS, INTRAVENOUS; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET MEMBRANE GLYCOPROTEINS; SUPPORT, NON-U.S. GOV'T; TYROSINE;

EID: 0027379391     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.88.4.1512     Document Type: Article

References (29)

1. Stein B, Fuster V, Israel DH, Cohen M, Badimon L, Badimon JJ, Chesebro JH. Platelet inhibitor agents in cardiovascular disease: an update. J Am Coll Cardiol. 1989;14:813-836.
2. Harker LA. Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. Am J Cardiol. 1987;60:20B-28B.
3. Coller BS. Antiplatelet agents in the prevention and therapy of thrombosis. Annu Rev Med. 1992;43:171-180.
4. Plow EF, Ginsberg MH. Cellular adhesion: GPIIb/IIIa as a prototypic adhesion receptor. Prog Hemost Thromb. 1988;9:117-156.
5. Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb-IIIa complex. Blood. 1988;71:831-843.
6. Coller BS. A new murine monoclonal antibody reports an activation dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest. 1985;76:101-108.
7. Coller BS, Folts JD, Scudder LE, Smith SR. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood. 1986;68:783-786.
8. Hanson SR, Pareti FI, Ruggeri ZM, Marzec UM, Kunicki TJ, Montgomery RR, Zimmerman TS, Harker LA. Effect of monoclonal antibodies against the platelet glycoprotein IIb/IIIa complex on thrombosis and hemostasis in the baboon. J Clin Invest. 1988; 81:149-158.
9. 2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest. 1990;86:651-659.
10. Ellis SG, Tcheng JE, Navetta FI, Muller DWM, Weisman HF, et al. Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty. Cor Art Dis. 1993;4: 167-175.
11. Pytela R, Pierschbacher MD, Ginsberg MH, Plow EF, Ruoslahti E. Platelet membrane glycoprotein IIbIIIa: member of a family of Arg-Gly-Asp specific adhesion receptors. Science. 1986;231: 1559-1562.
12. Plow EF, Pierschbacher MD, Ruoslahti E, Marguerie G, Ginsberg MH. The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets. Proc Natl Acad Sci U S A. 1985;82:8057-8061.
13. Gartner TK, Bennett JS. The tetrapeptide analogue of the cell attachment site of fibronectin inhibits platelet aggregation and fibrinogen binding to activated platelets. J Biol Chem. 1985;260: 11891-11894.
14. Dennis MS, Henzel WJ, Pitti RM, Lipari MT, Napier MA, Deisher TA, Bunting S, Lazarus RA. Platelet GPIIb/IIIa protein antagonists from snake venoms: evidence for a family of platelet aggregation inhibitors. Proc Natl Acad Sci U S A. 1990;87:2471-2475.
15. Huang TF, Holt JC, Lukasiewicz H, Niewiarowski S. Trigramin: a low molecular weight peptide inhibiting fibrinogen interaction with platelet receptors expressed on glycoprotein IIb/IIIa complex. J Biol Chem. 1987;262:16157-16163.
16. Gan ZR, Gould RJ, Jacobs JW, Friedman PA, Polokoff MA. Echistatin: a potent platelet aggregation inhibitor from the venom of the viper Echis carinatus. J Biol Chem. 1988;262:19827-19832.
17. Gould RJ, Polokoff MA, Friedman PA, Huang T-F, Holt JC, Cook JJ, Niewiarowski S. Disintegrins: a family of integrin inhibitory proteins from viper venoms. Proc Soc Exp Biol Med. 1990;195: 168-171.
18. Musial J, Niewiarowski S, Rucinski B, Stewart GJ, Cook JJ, Williams JA, Edmunds LH Jr. Inhibition of platelet adhesion to surfaces of extracorporeal circuits by disintegrins: RGD-containing peptides from viper venoms. Circulation. 1990;82:261-273.
19. Kouns WC, Kirchhofer D, Hadváry P, Edenhofer A, Weller T, Pfenninger G, Baumgartner HR, Jennings LK, Steiner B. Reversible conformational changes in grycoprotein IIb-IIIa by a potent and selective peptidomimetic inhibitor. Blood. 1992;80:2539-2547.
20. Roux SP, Tschopp TB, Kuhn H, Steiner B, Hadváry P. Effects of heparin, aspirin and a synthetic platelet glycoprotein IIb-IIIa receptor antagonist (Ro 43-5054) on coronary artery reperfusion and reocclusion after thrombolysis with tissue-type plasminogen activator in the dog. J Pharmacol Exp Ther. 1992;264:501-508.
21. Hartman GD, Egbertson MS, Halczenko W, Laswall WL, Duggan ME, Smith RL, Naylor AM, Manno PD, Lynch RJ, Zhang G, Chang CTC, Gould RJ. Non-peptide fibrinogen receptor antagonists: I. discovery and design of exosite inhibitors. J Med Chem. 1992;36:4640-4642.
22. Fraker PJ, Speck JC. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetra-chloro-3a,6a-diphenyl-glycoluril. Biochem Biophys Res Commun. 1978;80:849-857.
23. Marguerie GA, Plow EF, Edgington TS. Human platelets possess an inducible and saturable receptor specific for fibrinogen. J Biol Chem. 1979;254:5357-5363.
24. Mielke CH Jr, Kaneshiro MM, Maher IA, Weiner JM, Rapaport SI. The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood. 1969;34:204-215.
25. Coller BS, Scudder LE, Beer J, Gold HK, Folts JD, Cavagnaro J, Jordan R, Wagner C, Iuliucci J, Knight D, Ghrayeb J, Smith C, Weisman HF, Berger H. Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. Ann NY Acad Sci. 1991; 614:193-213.
26. Coller BS, Folts JD, Scudder LE, Smith SR. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental model. Blood. 1986;68:783-786.
27. Hanson SR. Platelet-specific antibodies as in vivo therapeutic reagents: a baboon model. In: Kunicki TJ, George JN, eds. Platelet Immunology: Molecular and Clinical Aspects. Philadelphia, Pa: JB Lippincott Co; 1989:471-483.
28. Yasuda T, Gold HK, Fallen JT, Leinbach RC, Guerrero JL, Scudder LE, Kanke M, Shealy D, Ross MJ, Collen D, Coller BS. A monoclonal antibody against the platelet GPIIIb/IIIa receptor prevents coronary artery reocclusion following reperfusion with recombinant tissue-type plasminogen activator in dogs. J Clin Invest. 1988;81:1284-1291.
29. Gold HK, Coller BS, Yasuda T, Saito T, Fallon JT, Guerrero JL, Leinbach RC, Ziskind AA, Collen D. Rapid and sustained coronary artery recanalization wilh combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal anti-platelet GPIIb/IIIa antibody in a dog model. Circulation. 1988; 77:670-677.